These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 21703180

  • 1. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
    Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, Schmutz G, Herrmann E.
    J Hepatol; 2011 Dec; 55(6):1235-40. PubMed ID: 21703180
    [Abstract] [Full Text] [Related]

  • 2. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S.
    AIDS; 2006 Oct 03; 20(15):1951-4. PubMed ID: 16988516
    [Abstract] [Full Text] [Related]

  • 3. Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
    Tan LK, Gilleece Y, Mandalia S, Murungi A, Grover D, Fisher M, Atkins M, Nelson M.
    J Viral Hepat; 2009 Jul 03; 16(7):471-8. PubMed ID: 19457140
    [Abstract] [Full Text] [Related]

  • 4. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.
    Antivir Ther; 2008 Jul 03; 13(3):341-8. PubMed ID: 18572746
    [Abstract] [Full Text] [Related]

  • 5. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M.
    J Antimicrob Chemother; 2005 Dec 03; 56(6):1087-93. PubMed ID: 16269552
    [Abstract] [Full Text] [Related]

  • 6. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection.
    Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S.
    Clin Gastroenterol Hepatol; 2015 Jun 03; 13(6):1181-8.e1. PubMed ID: 25460550
    [Abstract] [Full Text] [Related]

  • 7. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
    Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, Gerstoft J, Obel N.
    Scand J Infect Dis; 2012 Sep 03; 44(9):689-96. PubMed ID: 22680981
    [Abstract] [Full Text] [Related]

  • 8. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
    Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S.
    Clin Gastroenterol Hepatol; 2012 Aug 03; 10(8):941-6; quiz e68. PubMed ID: 22507876
    [Abstract] [Full Text] [Related]

  • 9. Tenofovir for the treatment of hepatitis B virus.
    Jenh AM, Thio CL, Pham PA.
    Pharmacotherapy; 2009 Oct 03; 29(10):1212-27. PubMed ID: 19792994
    [Abstract] [Full Text] [Related]

  • 10. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
    Agbaji OO, Agaba PA, Idoko JA, Taiwo B, Murphy R, Kanki P, Ekong E.
    West Afr J Med; 2011 Oct 03; 30(3):164-8. PubMed ID: 22120479
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK, 903 Study Team, 907 Study Team.
    J Infect Dis; 2004 Apr 01; 189(7):1185-92. PubMed ID: 15031786
    [Abstract] [Full Text] [Related]

  • 12. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
    Pradat P, Le Pogam MA, Okon JB, Trolliet P, Miailhes P, Brochier C, Maynard M, Bailly F, Zoulim F, Cotte L.
    J Viral Hepat; 2013 Sep 01; 20(9):650-7. PubMed ID: 23910650
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
    Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraqueiro G, Moucari R, Hamet G, Martinot-Peignoux M, Matheron S, Marcellin P.
    Liver Int; 2012 Jan 01; 32(1):93-101. PubMed ID: 22097898
    [Abstract] [Full Text] [Related]

  • 14. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N.
    J Pharm Pract; 2012 Oct 01; 25(5):552-9. PubMed ID: 22551561
    [Abstract] [Full Text] [Related]

  • 15. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Matthews GV, Cooper DA, Dore GJ.
    Antivir Ther; 2007 Oct 01; 12(1):119-22. PubMed ID: 17503756
    [Abstract] [Full Text] [Related]

  • 16. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
    Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, Katlama C.
    Antivir Ther; 2011 Oct 01; 16(2):199-205. PubMed ID: 21447869
    [Abstract] [Full Text] [Related]

  • 17. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
    Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P.
    J Hepatol; 2012 Mar 01; 56(3):520-6. PubMed ID: 22037226
    [Abstract] [Full Text] [Related]

  • 18. Effect of tenofovir on renal glomerular and tubular function.
    Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H.
    AIDS; 2007 Jul 11; 21(11):1483-5. PubMed ID: 17589197
    [Abstract] [Full Text] [Related]

  • 19. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.
    Guaraldi G, Roverato A, Giovanardi C, Ravera F, Squillace N, Orlando G, Cappelli G, Esposito R, Palella F.
    J Antimicrob Chemother; 2009 Feb 11; 63(2):374-9. PubMed ID: 19095683
    [Abstract] [Full Text] [Related]

  • 20. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR.
    J Viral Hepat; 2012 Mar 11; 19(3):213-9. PubMed ID: 22329376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.